You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):"苯甲酸阿格列汀片"獲藥品註冊批件
格隆匯 05-11 18:32

格隆匯5月11日丨石藥集團(01093.HK)宣佈,公司附屬公司石藥集團歐意藥業有限公司開發的"苯甲酸阿格列汀片(25mg)"已獲中華人民共和國國家藥品監督管理局頒發藥品註冊批件,並視同通過仿製藥質量和療效一致性評價。

苯甲酸阿格列汀是一種高度選擇性的二肽基肽酶-4(DPP-4)抑制劑,具有抗糖尿病的作用。該產品適用於治療2型糖尿病,單獨使用可作為飲食控制和運動的輔助治療,以改善2型糖尿病患者的血糖控制。當單獨使用鹽酸二甲雙胍仍不能有效控制血糖時,該產品可與鹽酸二甲雙胍聯合使用,在飲食和運動基礎上改善2型糖尿病患者的血糖控制。

該產品的獲批將進一步豐富集團在代謝疾病領域的產品線,為2型糖尿病患者提供新的選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account